Get started
Author

Lucy D. Burr

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
2018 · Dominic Keating, Gautham Marigowda, et al. · New England Journal of Medicine · 722
PDF
A Novel Microbiota Stratification System Predicts Future Exacerbations in Bronchiectasis
2014 · Geraint B. Rogers, Nur Masirah M. Zain, et al. · Annals of the American Thoracic Society · 244
The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial
2014 · Geraint B Rogers, Kenneth D Bruce, et al. · The Lancet Respiratory Medicine · 217
Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis
2019 · James D Chalmers, Wim Boersma, et al. · The Lancet Respiratory Medicine · 190
PDF
R othia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease
2021 · Charlotte Rigauts, Juliana Aizawa, et al. · European Respiratory Journal · 166
PDF
Airway Mucus Hyperconcentration in Non–Cystic Fibrosis Bronchiectasis
2019 · Kathryn A. Ramsey, Alice C. H. Chen, et al. · American Journal of Respiratory and Critical Care Medicine · 138
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
2025 · Claire Keating, Lael M Yonker, et al. · The Lancet Respiratory Medicine · 117
PDF
Matrix Metalloproteinases Vary with Airway Microbiota Composition and Lung Function in Non–Cystic Fibrosis Bronchiectasis
2015 · Steven L. Taylor, Geraint B. Rogers, et al. · Annals of the American Thoracic Society · 99
Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry
2019 · Simone K. Visser, Peter T.P. Bye, et al. · Respiratory Medicine · 94
PDF
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
2023 · Ahmet Z Uluer, Gordon MacGregor, et al. · The Lancet Respiratory Medicine · 74
Oxidative and endoplasmic reticulum stress in respiratory disease
2018 · Alice C‐H Chen, Lucy Burr, et al. · Clinical & Translational Immunology · 71
PDF
Opportunistic bacteria confer the ability to ferment prebiotic starch in the adult cystic fibrosis gut
2018 · Yanan Wang, Lex E.X. Leong, et al. · Gut Microbes · 65
PDF
GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection
2022 · Cheng Xiang Foo, Stacey Bartlett, et al. · European Respiratory Journal · 59
PDF
Targeting the P2Y13 Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental Asthma
2021 · Rhiannon B. Werder, Md Ashik Ullah, et al. · American Journal of Respiratory and Critical Care Medicine · 58
The impact of CFTR modulator therapies on CF airway microbiology
2019 · Geraint B. Rogers, Steven L. Taylor, et al. · Journal of Cystic Fibrosis · 57
PDF
Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis
2018 · Jocelyn M. Choo, Guy C. J. Abell, et al. · mSphere · 53
FUT2genotype influences lung function, exacerbation frequency and airway microbiota in non-CF bronchiectasis
2016 · Steven L Taylor, Richard J Woodman, et al. · Thorax · 47
PDF
Management of Australian Adults with Bronchiectasis in Tertiary Care: Evidence-Based or Access-Driven?
2019 · Simone K. Visser, Peter T. P. Bye, et al. · Lung · 36
Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non–Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial
2016 · Lucy D. Burr, Geraint B. Rogers, et al. · Annals of the American Thoracic Society · 36
Emotion regulation mediates the effects of sleep on stress and aggression
2022 · Olivia P. Demichelis, Sarah A. Grainger, et al. · Journal of Sleep Research · 33
PDF
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study
2025 · Oriol Sibila, Jamie Stobo, et al. · The Lancet Respiratory Medicine · 30
Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis
2024 · Haressh Sajiir, Sahar Keshvari, et al. · Nature Communications · 30
Efficacy of biologically-directed daylight therapy on sleep and circadian rhythm in Parkinson's disease: a randomised, double-blind, parallel-group, active-controlled, phase 2 clinical trial
2024 · Beatrix Feigl, Simon J.G. Lewis, et al. · EClinicalMedicine · 28
PDF
Adult Non-Cystic Fibrosis Bronchiectasis Is Characterised by Airway Luminal Th17 Pathway Activation
2015 · Alice C.-H. Chen, Megan L. Martin, et al. · PLoS ONE · 24
PDF
The cystic fibrosis gut as a potential source of multidrug resistant pathogens
2020 · Steven L. Taylor, Lex E.X. Leong, et al. · Journal of Cystic Fibrosis · 23
PDF
Works count: 107
Citation count: 3,140
H-index: 24
I10-index: 40
Year
Topic
Type